Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BCDA BioCardia Inc
- Stocks
- Healthcare
- NASDAQ: BCDA
Price (delayed)
$2.17
Market cap
$11.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.33
Enterprise value
$11.14M
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's
Highlights
The EPS has soared by 67% YoY and by 20% from the previous quarter
The equity is up by 33% year-on-year
BCDA's quick ratio has plunged by 72% from the previous quarter but it is up by 16% YoY
BioCardia's net income has increased by 19% YoY but it has decreased by 6% from the previous quarter
BioCardia's gross profit has plunged by 99% YoY and by 95% from the previous quarter
BioCardia's revenue has plunged by 99% YoY and by 95% from the previous quarter
Key stats
What are the main financial stats of BCDA
Market
Valuations
Earnings
Shares outstanding
5.18M
Market cap
$11.24M
Enterprise value
$11.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3,353.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,712.34
Revenue
$3,000
Gross profit
$3,000
Operating income
-$8.45M
Net income
-$8.39M
EBIT
-$8.39M
EBITDA
-$7.96M
Free cash flow
-$8.12M
Per share
Balance sheet
Liquidity
EPS
-$2.33
EPS diluted
-$2.33
Free cash flow per share
-$1.75
Book value per share
-$0.32
Revenue per share
$0
TBVPS
$0.47
Total assets
$2.17M
Total liabilities
$3.69M
Debt
$850,000
Equity
-$1.52M
Working capital
-$2.06M
Debt to equity
-0.56
Current ratio
0.36
Quick ratio
0.29
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-265,266.7%
Gross margin
100%
Net margin
-279,700%
Operating margin
-281,733.3%
Return on assets
-223.1%
Return on equity
-30,792.7%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-279,700%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCDA stock price
How has the BioCardia stock price performed over time
Intraday
-0.46%
1 week
2.84%
1 month
-19.03%
1 year
-50.9%
YTD
-0.46%
QTD
-14.57%
Financial performance
How have BioCardia's revenue and profit performed over time
Revenue
$3,000
Gross profit
$3,000
Operating income
-$8.45M
Net income
-$8.39M
Gross margin
100%
Net margin
-279,700%
BioCardia's gross profit has plunged by 99% YoY and by 95% from the previous quarter
BioCardia's revenue has plunged by 99% YoY and by 95% from the previous quarter
BioCardia's net income has increased by 19% YoY but it has decreased by 6% from the previous quarter
BioCardia's operating income has increased by 19% YoY but it has decreased by 6% from the previous quarter
Price vs fundamentals
How does BCDA's price correlate with its fundamentals
Growth
What is BioCardia's growth rate over time
Valuation
What is BioCardia stock price valuation
P/E
N/A
P/B
N/A
P/S
3,353.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,712.34
The EPS has soared by 67% YoY and by 20% from the previous quarter
The equity is up by 33% year-on-year
BioCardia's revenue has plunged by 99% YoY and by 95% from the previous quarter
Efficiency
How efficient is BioCardia business performance
The ROA has grown by 15% YoY but it has contracted by 9% from the previous quarter
Dividends
What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCDA.
Financial health
How did BioCardia financials performed over time
BCDA's total assets is 41% lower than its total liabilities
BCDA's quick ratio has plunged by 72% from the previous quarter but it is up by 16% YoY
BCDA's current ratio has shrunk by 68% QoQ but it is up by 16% YoY
The debt is 156% greater than the equity
BioCardia's debt to equity has plunged by 149% from the previous quarter and by 3.7% YoY
The equity is up by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.